Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Oct 15, 2021; 13(10): 1518-1531
Published online Oct 15, 2021. doi: 10.4251/wjgo.v13.i10.1518
Published online Oct 15, 2021. doi: 10.4251/wjgo.v13.i10.1518
Groups | At beginning (g) | At 90 d (g) | At the end of life (g) |
Control | 329.8 ± 14.41 | 459.6 ± 15.6 | 563.0 ± 40.5 |
Control-P | 280.2 ± 11.3 | 459.6 ± 14.7 | 619.3 ± 42.0 |
DMH | 361.0 ± 17.6 | 451.2 ± 22.5 | 592.8 ± 52.2 |
DMH-P | 361.0 ± 17.6 | 473.7 ± 23.7 | 592.8 ± 52.2 |
DMH-C | 299.0 ± 15.7 | 412.4 ± 17.1 | 493.0 ± 67.0 |
DMH-P-C | 292.1 ± 34.6 | 412.7 ± 26.1 | 559.8 ± 91.9 |
- Citation: Gigola G, Carriere P, Novoa Díaz MB, Perdigon G, Zwenger AO, Gentili C. Survival effect of probiotics in a rat model of colorectal cancer treated with capecitabine. World J Gastrointest Oncol 2021; 13(10): 1518-1531
- URL: https://www.wjgnet.com/1948-5204/full/v13/i10/1518.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i10.1518